Add to ORKGAims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients with the metabolic syndrome. Methods and results Patients with the metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) 3.36 mmol/L (130 mg/dL) and multiple risk factors conferring a 10-year coronary heart disease risk score of.10 % were randomized (2:2:1) to receive rosuvastatin 10 mg, atorvastatin 10 mg, or placebo for 6 weeks. Subsequently, the rosuvastatin 10 mg and placebo groups received rosu
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low...
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Aims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients wi...
Item does not contain fulltextAIMS: The efficacy and safety of rosuvastatin, atorvastatin, and place...
AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are ava...
Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslip...
Background. Most studies investigating the benefits of statins have focused on North American and Eu...
We determined the effect of 6-month rosuvastatin treatment on blood lipids, oxidative parameters, ap...
Aim: The aim of the current study was to determine the efficacy of the 4 most commonly prescribed st...
Background: Metabolic syndrome (MetS) is a constellation of cardiometabolic risk determinants compri...
Background. International guidelines emphasize the need to achieve recommended low-density lipoprote...
Background: International guidelines emphasize the need to achieve recommended low-density lipoprote...
Objectives. To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with...
AbstractBackground:The majority of clinical trials investigating the clinical benefits of lipid-lowe...
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low...
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Aims The efficacy and safety of rosuvastatin, atorvastatin, and placebo were compared in patients wi...
Item does not contain fulltextAIMS: The efficacy and safety of rosuvastatin, atorvastatin, and place...
AIM: The metabolic syndrome (MS) increases the risk of coronary heart disease, yet few data are ava...
Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslip...
Background. Most studies investigating the benefits of statins have focused on North American and Eu...
We determined the effect of 6-month rosuvastatin treatment on blood lipids, oxidative parameters, ap...
Aim: The aim of the current study was to determine the efficacy of the 4 most commonly prescribed st...
Background: Metabolic syndrome (MetS) is a constellation of cardiometabolic risk determinants compri...
Background. International guidelines emphasize the need to achieve recommended low-density lipoprote...
Background: International guidelines emphasize the need to achieve recommended low-density lipoprote...
Objectives. To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with...
AbstractBackground:The majority of clinical trials investigating the clinical benefits of lipid-lowe...
Background: Patients at high risk of cardiovascular disease frequently fail to reach recommended low...
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...